Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
Kymera Therapeutics announced early completion of enrollment in its Phase 2b BROADEN2 clinical trial for KT-621, an oral STAT6 degrader targeting moderate to severe atopic dermatitis. This accelerated enrollment allows for topline data readout by year-end 2026, six months ahead of schedule, and plans to initiate Phase 3 trials by mid-2027. KT-621 i…